microdialysis neurotoxicity studies of quinoline and isoquinoline
derivatives related to MPTP/MPP1. Neurosci. Lett. 100, 306–312.
Callier S., Morissette M., Grandbois M. and di Paolo T. (2000)
Stereospecific prevention by 17b-estradiol of MPTP-induced
dopamine depletion in mice. Synapse 37, 245–251.
Chalon S., Emond P., Bodard S., Vilar M.-P., Thiercelin C., Besnard
J.-C. and Guilloteau D. (1999) Time course of changes in striatal
dopamine transporters and D2 receptors with specific iodinated
markers in a rat model of Parkinson ́ıs disease. Synapse 31,
134–139.
Collins M. A. and Neafsey E. J. (1985) b-Carboline analogues
N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism? Neurosci.
Lett. 55, 179–184.
Dewey S. L., Smith G. S., Logan J., Brodie J. D., Fowler J. S. and Wolf
A. P. (1993) Striatal binding of the PET ligand 11C-raclopride is
altered by drugs that modify synaptic dopamine levels. Synapse
13, 350–356.
Donnan G. A., Kaczmarczyk S. J., Rowe P. J., Figdor R. and
Mendelsohn F. A. O. (1986) The effects of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine on presynaptic dopamine uptake sites
in the mouse striatum. J. Neurol. Sci. 74, 111–119.
Dostert P., Strolin-Benedetti M. and Dordain G. (1988) Dopaminederived alkaloids in alcoholism and in Parkinson's and
Huntington's disease. J. Neural Transm. 74, 61–74.
Doudet D. J., Holden J. E., Jivan S., McGeer E. and Wyatt R. J. (2000)
In vivo PET studies of the dopamine D2 receptors in rhesus
monkeys with long-term MPTP-induced parkinsonism. Synapse
38, 105–113.
Eberling J. L., Bankiewicz K. S., Pivirotto P., Bringas J., Chen K.,
Nowotnik D. P., Steiner J. P., Budinger T. F. and Jagust W. J.
(1999) Dopamine transporter loss and clinical changes in MPTPlesioned primates. Brain Res. 832, 184–187.
Ferger B., Teismann P., Earl C. D., Kuschinsky K. and Oertel W. H.
(1999) Salicylate protects against MPTP-induced impairments in
dopaminergic neurotransmission at the striatal and nigral level in
mice. Naunyn Schmiedebergs Arch. Pharmacol. 360, 256–261.
Gerlach M. and Riederer P. (1996) Animal models of Parkinson ́ıs
disease: an empirical comparison with the phenomenology of the
disease in man. J. Neural Transm. 103, 987–1041.
Goulet M., Morissette M., Grondin R., Falardeau P. B., Be ́dard P. J.,
Roste`ne W. and di Paolo T. (1999) Neurotensin receptors and
dopamine transporters: effects of MPTP lesioning and chronic
dopaminergic treatments in monkeys. Synapse 32, 153–164.
Hartvig P., Torstenson R., Tedroff J., Watanabe Y., Fasth K. J., Bjurling
P. and La°ngstro ̈m B. (1997) Amphetamine effects on dopamine
release and synthesis rate studied in the rhesus monkey brain by
positron emission tomography. J. Neural Transm. 104, 329–339.
Hume S. P., Opacka-Juffry J., Myers R., Ahier R. G., Ashworth S.,
Brooks D. J. and Lammertsma A. A. (1995) Effect of l-dopa and
6-hydroxydopamine lesioning on [11C]raclopride binding in rat
striatum, quantified using PET. Synapse 21, 45–53.
Joyce J. N., Marshall J. F., Bankiewicz K. S., Kopin I. J. and Jacobowitz
D. M. (1986) Hemiparkinsonism in a monkey after unilateral
internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) is associated with regional ipsilateral
changes in striatal dopamine D-2 receptor density. Brain Res. 382,
360–364.
Kilbourn M. R., Mulholland G. K., Sherman P. S. and Pisani T. (1991)
In vivo binding of the dopamine uptake inhibitor [18F]GBR 13119
in MPTP-treated C57BL/6 mice. Nucl. Med. Biol. 18, 803–806.
Kilbourn M. R., Kuszpit K. and Sherman P. (2000) Rapid and
differential losses of in vivo dopamine transporter (DAT) and
